28 October 2021

Joint symposium with the ISHLT: End-stage PAH - how and what do we do in 2021?

Watch the replay

Agenda

  • John Granton // When should a PH patient be considered for lung transplant?
  • Erika Rosenzweig // Atrial septum defect creation or mechanical support for end-stage PAH
  • Eugene Golts // Lung and Heart-lung Transplant in 2021 – how well do PAH patients do?
  • Ulrich Martin // Pluripotent stem cell-based approaches and the future of artificial lungs
  • Ryan Tedford // Timing and extent of ventricular reverse remodelling after lung transplant for PH

Poll results

Beginning of webinar results (18 responses)

1. Talk 1: Improving survival AND quality of life are equally important considerations when considering timing of transplantation for PAH.

Agree - 100%

Disagree - 0%

 

2. Talk 2: Atrial septostomy can be used as a palliative bridge for end-stage PAH?

Agree - 66.67%

Disagree - 33.33%

 

3. Talk 3: the timing of referral for the Lung Transplantation for Pulmonary Hypertension should be solely determined based on available risk calculators?

Yes - 27.78%

No - 72.22%

 

4. Talk 4: Treatment of pulmonary arterial hypertension via iPS-based cellular therapies will become reality during the next 15 years

Yes - 72.22% 

No - 27.78%

 

5. Talk 5: Patients with end-stage PAH and very severe RV dysfunction should be considered for heart-lung transplant rather than isolated (bilateral) lung

Yes - 66.67%

No - 33.33%

 

End of webinar results (6 responses)

1. Talk 1: Improving survival AND quality of life are equally important considerations when considering timing of transplantation for PAH.

Agree - 100%

Disagree - 0%

 

2. Talk 2: Atrial septostomy can be used as a palliative bridge for end-stage PAH?

Agree - 100%

Disagree - 0%

 

3. Talk 3: the timing of referral for the Lung Transplantation for Pulmonary Hypertension should be solely determined based on available risk calculators?

Yes - 33.33% 

No - 66.67%

 

4. Talk 4: Treatment of pulmonary arterial hypertension via iPS-based cellular therapies will become reality during the next 15 years

Yes - 33.33% 

No - 66.67%

 

5. Talk 5: Patients with end-stage PAH and very severe RV dysfunction should be considered for heart-lung transplant rather than isolated (bilateral) lung

Yes - 50%

No - 50%


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg